Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Passage Bio ( (PASG) ) just unveiled an update.
On July 28, 2025, Passage Bio, Inc. announced that it has regained compliance with Nasdaq Listing Rule 5450(a)(1) as its stock price has met the required minimum bid price of $1.00 per share for 10 consecutive business days. This resolution closes a listing matter that began on August 1, 2024, when the company was notified of non-compliance due to its stock price falling below the minimum requirement for 30 consecutive days.
The most recent analyst rating on (PASG) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Passage Bio stock, see the PASG Stock Forecast page.
Spark’s Take on PASG Stock
According to Spark, TipRanks’ AI Analyst, PASG is a Neutral.
Passage Bio scores moderately low due to its financial challenges, including no revenue and significant cash burn. However, a strong balance sheet and recent corporate event announcements, including program advancements and extended cash runway, provide some optimism. Technical indicators suggest a neutral to bearish sentiment, and traditional valuation metrics are limited due to the company’s stage and lack of profitability.
To see Spark’s full report on PASG stock, click here.
More about Passage Bio
Average Trading Volume: 44,329
Technical Sentiment Signal: Sell
Current Market Cap: $22M
See more insights into PASG stock on TipRanks’ Stock Analysis page.